Frequency of polymorphic variants in corticotropin releasing hormone receptor 1, glucocorticoid induced 1 and Fc fragment of IgE receptor II genes in healthy and asthmatic Tamilian population

Revathy N., Adithan C., Vinod Kumar S., Kadhiravan T., Sandhiya S., Manju R., Vignesh K., Saranyarani P.


Background: Asthma is a chronic airway inflammatory disease characterized by increased hyper-responsiveness and recurrent episodes of reversible obstructions. Asthma pharmacogenomic studies report significant association of single nucleotide polymorphisms (SNPs) in genes corticotropin releasing hormone receptor 1 (CRHR1), Fc fragment of IgE receptor II (FCER2) and glucocorticoid induced 1 (GLCCI1) with inhaled corticosteroid (ICS) response. The present study was aimed to establish the allelic and genotypic frequencies of polymorphisms rs242941, rs28364072 & rs37972 in CRHR1, FCER2 and GLCCI1 genes, respectively in Tamilian healthy population and asthma patients and to compare with established frequencies of global populations.

Methods: The study groups consisted of healthy volunteers and persistent asthma patients who were drug naïve or without ICS treatment in the last ≥2 months, attending JIPMER hospital (n=111 and 78, respectively). SNP genotyping was done using PCR-RFLP (polymerase chain reaction-restriction fragment length polymorphism) and real time-PCR methods.

Results: Allelic and genotypic frequencies for all the studied variants found to be in hardy-weinberg equilibrium with minor allele frequencies (MAF) of rs 242941, rs 28364072 and rs 37972 at 0.51, 0.33 and 0.38, respectively, in healthy population. No significant difference in gene frequencies was obtained between healthy control and asthma patient groups. Significant difference in allele frequencies was observed between Tamilian healthy and specific global populations. West African frequency was found to be significantly different for all 3 SNPs (p<0.0001).

Conclusions: MAF of rs 242941, rs 28364072 and rs 37972 were 0.51, 0.33 and 0.38, respectively in Tamilian population which were significantly different from various global populations. The frequency distribution found helps to further with ICS response association studies in larger cohorts of asthma patients.


Asthma, Tamilian, CRHR1, FCER2, GLCCI1

Full Text:



GINA report, global strategy for asthma management and prevention. Available at: Accessed on 30 January 2016.

Song WJ, Kang MG, Chang YS, Cho SH. Epidemiology of adult asthma in Asia: toward a better understanding. Asia Pac Allergy. 2014;4:75-85.

To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012;12:204.

Research C for DE and genomics-table of pharmacogenomic biomarkers in drug labeling. Available at http: // www. /drugs / scienceresearch/ researchareas/ pharmacogenetics /u cm083378.htm. Accessed on 30 January 2016.

Szefler SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol. 2002;109:410-8.

CRHR1 corticotropin releasing hormone receptor 1. Available at http:// /gene /1394. Accessed on 30 January 2016.

Tantisira KG, Lake S, Silverman ES, Palmer LJ, Lazarus R, Silverman EK, et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet. 2004;13:1353-9.

Tantisira KG, Lazarus R, Litonjua AA, Klanderman B, Weiss ST. Chromosome 17: association of a large inversion polymorphism with corticosteroid response in asthma. Pharmacogenet Genomics. 2008;18:733-7.

Awasthi S, Gupta S, Agarwal S, Sharma N. CRHR1 gene SNPs and response to systemic corticosteroids in Indian asthmatic children during acute exacerbation. Indian J Pediatr. 2015;82:781-6.

Rogers AJ, Tantisira KG, Fuhlbrigge AL, Litonjua AA, Lasky SJA, Szefler SJ, et al. Predictors of poor response during asthma therapy differ with definition of outcome. Pharmacogenomics. 2009;10:1231-42.

Tsartsali L, Papadopoulos M, Lagona E, Papadimitriou A, Kanaka GC, Louizou E, et al. Association of hypothalamic-pituitary-adrenal axis-related polymorphisms with stress in asthmatic children on inhaled corticosteroids. Neuro Immunomodulation. 2012;19:88-95.

Mougey EB, Chen C, Tantisira KG, Blake KV, Peters SP, Wise RA, et al. Pharmacogenetics of asthma controller treatment. Pharmacogenomics J. 2013;13:242-50.

Liu Z, Zhu F, Wang G, Xiao Z, Wang H, Tang J, et al. Association of corticotropin-releasing hormone receptor1 gene SNP and haplotype with major depression. Neurosci Lett. 2006;404:358-62.

Xiao Z, Liu W, Gao K, Wan Q, Yang C, Wang H, et al. Interaction between CRHR1 and BDNF Genes Increases the risk of recurrent major depressive disorder in Chinese population. PLoS One. 2011;6:28733.

Liu Z, Zhu F, Wang G, Xiao Z, Tang J, Liu W, et al. Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. Neurosci Lett. 2007;414:155-8.

Licinio J, Kirwan OF, Irizarry K, Merriman B, Thakur S, Jepson R, et al. Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Mol Psychiatry. 2004;9:1075-82.

Ventura JR, Symon A, Lopez P, Fiedler JL, Rojas G, Heskia C, et al. Relationship of cortisol levels and genetic polymorphisms to antidepressant response to placebo and fluoxetine in patients with major depressive disorder: a prospective study. BMC Psychiatry. 2014;14:220.

GLCCI1 glucocorticoid induced 1. Available at: Accessed at 28 January 2016.

Tantisira KG, Lasky SJ, Harada M, Murphy A, Litonjua AA, Himes BE, et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med. 2011;365:1173-83.

Vijverberg SJH, Tavendale R, Leusink M, Koenderman L, Raaijmakers JAM, Postma DS, et al. Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma populations with a reported use of inhaled corticosteroids. Pharmacogenomics. 2014;15:799-806.

Cheong HI, Kang HG, Schlondorff J. GLCCI1 single nucleotide polymorphisms in pediatric nephrotic syndrome. Pediatr Nephrol Berl Ger. 2012;27:1595-9.

FCER2 Fc fragment of IgE, low affinity II, receptor for (CD23) (Homo sapiens (human)) - Gene-NCBI. Available at http:// www. ncbi. nlm. nih. gov /gene/2208. Accessed on 30 January 2016.

Tantisira KG, Silverman ES, Mariani TJ, Xu J, Richter BG, Klanderman BJ, et al. FCER2: A pharmacogenetic basis for severe exacerbations in children with asthma. J Allergy Clin Immunol. 2007;120:1285-91.

Koster ES, Maitland ZAH, Tavendale R, Mukhopadhyay S, Vijverberg SJH, Raaijmakers JM, et al. FCER2 T2206C variant associated with chronic symptoms and exacerbations in steroid-treated asthmatic children. Allergy. 2011;66:1546-52.

Sharma N, Dixit P, Awasthi S, Phadke SR. Genetic variations of the FCER2 gene and asthma susceptibility in north Indian children: a case-control study. Biomarkers. 2013;18:660-7.

Sambrook J, Russell DW. Commonly used techniques in molecular cloning. Appendix 8: In: Molecular cloning: a laboratory manual. Vol 3. 3rd Edn. Cold spring harbor laboratory press, cold spring Harbor, New York; 2001:A8-10.

Sharma N, Awasthi S, Phadke SR, Gupta S, Agrawal S. Development and validation of a PCR-RFLP method to genotype the CRHR1 (rs 242941: G> T)) gene variation: a simple and inexpensive pharmacogenetic tool. J Bio Innov. 2013;2:79-89.

Al MS, Vazquez TA, Jamhawi A, Aldosari MS, Mahboub B, Iqbal N, et al. Rs 37972 and rs 37973 single-nucleotide polymorphisms in the glucocorticoid-inducible 1 gene are not associated with asthma risk in a Saudi Arabian population. J Asthma. 2015;52:115-22.

Szalai R, Matyas P, Varszegi D, Melegh M, Magyari L, Jaromi L, et al. Admixture of beneficial and unfavourable variants of GLCCI 1 and FCER 2 in Roma samples can implicate different clinical response to corticosteroids. Mol Biol Rep. 2014;41:7665-9.

Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, et al. Strengthening the reporting of genetic association studies (STREGA) - an extension of the STROBE statement. Eur J Clin Invest. 2009;39:247-66.